The League against cancer denounces the exorbitant prices of treatments. Glivec, 37,000 euros per year, Sovaldi, 41,000 euros or the Keytruda, soon to be sold for more than 100,000 euros. For drug manufacturers, these prices are explained by the cost of research and for them, it is necessary to take into account the savings that these treatments make it possible to achieve. “When you transform chemotherapy that was administered in the hospital, into tablets that you take in town, you generate extraordinary savings“, notes Éric Baseilhac, director of economic affairs at LEEM.
However, at the moment, cancer treatments continue to flare up. Prices which should be multiplied by seven between 2004 and 2020. They now represent 10% of social security expenditure. A situation denounced by the League Against Cancer, especially since the laboratories adapt their prices according to the country. Thus, the same drug is available for 40,000 euros in France, against less than 1,000 euros in Egypt.
